MEV for Retroclavicular Approach to Infraclavicular Block
- Conditions
- Bupivacaine
- Registration Number
- NCT03555786
- Lead Sponsor
- Antalya Training and Research Hospital
- Brief Summary
In this study, the primary objective was to estimate the minimum effective volume of bupivacaine 0.5% resulting in successful block in 90% of patients (MEV90) for ultrasound-guided retroclavicular approach to infraclavicular brachial plexus block.
- Detailed Description
A "biased coin up-and-down sequential design" will be applied to assess the minimum effective volume in 90% of patients for the retroclavicular brachial plexus block. The first subject received 25 ml 0.5% bupivacaine . Each subsequent patient received a dose that depended on the response of the previous one. If the previous block is successful, the block will be performed either by a reduction of the volume by 2.5 ml with a probability ß = 0.11 or by a same dose of the previous one with a probability 1-ß = 0.89 in the next patient.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 45
- patients who received infraclavicular brachial plexus block for elective elbow, forearm, wrist, or hand surgery
- American Society of Anesthesiologists class I, II or III
- patients <18 years old
- >65 years old
- body mass index (BMI) <20 or >35 kg/m2
- inability to provide written informed consent
- refusal of regional anesthesia
- pregnancy
- contraindication for regional anesthesia
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The minimum effective volume of bupivacaine 0.5% resulting in successful block in 90% of patients (MEV90) 30 minutes The determination of MEV90 and its 95% confidence interval (CI) will be based on a "biased coin up-and-down sequential design
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Antalya Training and Research Hospital
🇹🇷Antalya, Turkey